Showing 6751-6760 of 7509 results for "".
- Fractional HiFR Helps Fight Signs of Aging on Lower Face/Neckhttps://practicaldermatology.com/news/fractional-hifr-helps-fight-signs-of-aging-on-lower-faceneck/2458469/Fractional high intensity focused radiofrequency (HiFR) is safe and effective in the treatment of mild to moderate laxity of the lower face and neck, new research suggests. The study was selected as Editor’s Choice in the July 2016 issue of
- Valeant Dermatology ASPIRE HIGHER Scholarship Program Names Winnershttps://practicaldermatology.com/news/valeant-dermatology-aspire-higher-scholarship-program-names-winners/2458472/Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, announced the winners of its ASPIRE HIGHER Scholarship Program. Nine undergraduate and graduate students were selected from a pool of 970 applicants and awarded up to $10,000 each tow
- Dr. Reddy's Sernivo Officially Debuts at NYC Media Eventhttps://practicaldermatology.com/news/dr-reddys-sernivo-officially-debuts-at-nyc-event/2458473/Calling Sernivo (betamethasone dipropionate) Spray 0.05% a ‘trifecta’ for dermatologists who treat mild-to-moderate psoriasis, Josh Zeichner, MD, introduced members of the New York City media to the new spray-on steroid. “It is effe
- BEVL Blasts Off: New Mobile Network Seeks to Connect Aesthetic Proshttps://practicaldermatology.com/news/bevl-blasts-off-new-mobile-network-seeks-to-connect-aesthetic-pros/2458474/Meet BEVL, a new mobile network that connects medical aesthetics professionals. In private beta testing since June, BEVL is now accessible via iOS, Android and th
- Skinbetter scienceTM Debuts with Launch of New Anti-aging Productshttps://practicaldermatology.com/news/skinbetter-sciencetm-debuts-with-launch-of-new-anti-aging-products/2458478/Introducing skinbetter scienceTM ... the brainchild of Jonah Shacknai and several former members of the Medicis leadership team among others. The new line will debut in physician offices nationwide in August 2016. The
- Deadline Approaching: Apply for Grant from La Roche-Posay's "Dermatologist from the Heart" Programhttps://practicaldermatology.com/news/deadline-approaching-apply-for-grant-from-la-roche-posays-dermatologist-from-the-heart-program/2458476/La Roche-Posay plans to continue its "Dermatologist from the Heart" program for the fifth year. As part of the program, La Roche-Posay provides grant money up to $10,000 to fund community-oriented projects that ma
- BTL Aesthetics Announces FDA Clearance for Thighshttps://practicaldermatology.com/news/btl-aesthetics-announces-fda-clearance-for-thighs/2458475/The FDA awarded BTL Aesthetics a new designation for it non-invasive fat reduction treatment, BTL Vanquish ME—the treatment is now FDA-cleared for the circumferential reduction of the abdomen and thighs. The clearance was secured following several rounds of clinical testing to provide ample
- MRF to UPSTF: Reconsider Supporting Annual Skin Cancer Checkshttps://practicaldermatology.com/news/mrf-to-upstf-reconsider-support-for-annual-skin-cancer-checks/2458479/The Melanoma Research Foundation (MRF) is urging the U.S. Preventive Services Task Force’s (USPSTF) to reconsider their recent announcement stating that insufficient data exists to support a recommendation for annual skin canc
- ASDS Disagrees with New Skin Cancer Screening Recommendationhttps://practicaldermatology.com/news/asds-disagrees-with-new-skin-cancer-screening-recommendation/2458483/The US Preventive Service Task Force (USPSTF) has declined to take a stance on the value of preventive skin cancer screenings for the second time in seven years, and The American Society for Dermatologic Surgery ASDS is responding with disappointment. The USPSTF says there is insufficient
- Study: 98% of Head Lice in at Least 42 States Now Resistant to Common OTC Treatmentshttps://practicaldermatology.com/news/98-of-head-lice-in-at-least-42-states-now-resistant-to-common-otc-treatments/2458480/Fully 98 percent of head lice in at least 42 states are resistant to various over-the-counter pyrethrins and pyrethroids including permethrin, which is the active ingredient in popular treatment formulations for pediculosis (Nix® (permethrin 1%), according to a study in t